The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Akero Therapeutics Inc (NASDAQ: AKRO) closed at $28.71 in the last session, down -6.21% from day before closing price of $30.61. In other words, the price has decreased by -$6.21 from its previous closing price. On the day, 0.74 million shares were traded. AKRO stock price reached its highest trading level at $30.66 during the session, while it also had its lowest trading level at $27.82.
Ratios:
We take a closer look at AKRO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 17.25 and its Current Ratio is at 17.25. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on November 18, 2024, initiated with a Buy rating and assigned the stock a target price of $65.
On September 19, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $69.Cantor Fitzgerald initiated its Overweight rating on September 19, 2023, with a $69 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 16 ’24 when Lamy Patrick sold 1,000 shares for $29.13 per share. The transaction valued at 29,130 led to the insider holds 34,258 shares of the business.
Yale Catriona sold 9,074 shares of AKRO for $264,117 on Dec 16 ’24. The Chief Development Officer now owns 95,648 shares after completing the transaction at $29.11 per share. On Dec 17 ’24, another insider, Rolph Timothy, who serves as the Chief Scientific Officer of the company, sold 3,800 shares for $31.10 each. As a result, the insider received 118,172 and left with 178,337 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 2003934976 and an Enterprise Value of 1323045504.
Stock Price History:
Over the past 52 weeks, AKRO has reached a high of $37.00, while it has fallen to a 52-week low of $15.32. The 50-Day Moving Average of the stock is -6.90%, while the 200-Day Moving Average is calculated to be 10.71%.
Shares Statistics:
According to the various share statistics, AKRO traded on average about 582.00K shares per day over the past 3-months and 583440 shares per day over the past 10 days. A total of 69.61M shares are outstanding, with a floating share count of 58.52M. Insiders hold about 16.16% of the company’s shares, while institutions hold 92.02% stake in the company. Shares short for AKRO as of 1732838400 were 3287084 with a Short Ratio of 5.65, compared to 1730332800 on 3820964. Therefore, it implies a Short% of Shares Outstanding of 3287084 and a Short% of Float of 4.8499998.
